This review highlights AI's role in improving diagnostic accuracy and quantifying biomarkers in dry eye disease, indicating significant advancements in personalized treatment.
Dry eye disease (DED) is a multifactorial ocular surface disorder characterized by ocular discomfort, visual disturbances, and potential structural damage. The heterogeneous etiology and symptomatology of DED pose significant challenges for accurate diagnosis and effective treatment. In recent years, artificial intelligence (AI), particularly deep learning (DL), has shown substantial promise in improving the objectivity and efficiency of DED assessment. This review provides a comprehensive synthesis of AI-assisted techniques for the quantification of key DED biomarkers, including tear film stability [e.g., tear meniscus height (TMH) and tear film break-up time (TBUT)], meibomian gland morphology, and corneal epithelial damage. We discuss how these technologies enhance diagnostic accuracy, standardize evaluation, and support personalized treatment. Collectively, these advancements underscore the transformative potential of AI in reshaping DED diagnostics and management.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: